Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CCR6 | P51684 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | PRKCA | P17252 | 14/20 | 0.36 |
| ▸ | PRKCE | Q02156 | 6/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6332600 | 0.95 | RAB9A (0.43) | RAB9AKDM4EL3MBTL1POLBMAPT | |
| SCHEMBL6330256 | 0.89 | RAB9A (0.46) | RAB9AKDM4EL3MBTL1POLBMAPT | |
| SCHEMBL6325134 | 0.87 | KDM4E (0.54) | RAB9AKDM4EL3MBTL1CCR6NFKB1 | |
| SCHEMBL6325136 | 0.87 | KDM4E (0.54) | RAB9AKDM4EL3MBTL1CCR6NFKB1 | |
| SCHEMBL6325029 | 0.86 | RAB9A (0.46) | RAB9AKDM4EL3MBTL1POLBMAPT | |
| SCHEMBL6330248 | 0.84 | MAPT (0.53) | RAB9AL3MBTL1POLBMAPTNFKB1 | |
| SCHEMBL6331187 | 0.83 | KDM4E (0.51) | RAB9AKDM4EL3MBTL1CCR6NFKB1 | |
| SCHEMBL6328042 | 0.83 | KDM4E (0.51) | RAB9AKDM4EL3MBTL1CCR6NFKB1 | |
| SCHEMBL6331189 | 0.83 | KDM4E (0.51) | RAB9AKDM4EL3MBTL1CCR6NFKB1 | |
| SCHEMBL6328046 | 0.83 | KDM4E (0.51) | RAB9AKDM4EL3MBTL1CCR6NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050009928-A1 | Cyclopentanone derivative | ZEON CORPORATION (JP) | 2005-01-13 | — | — | US | disclosed |
| EP-1420005-A1 | CYCLOPENTANONE DERIVATIVE | Zeon Corporation (JP) | 2004-05-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009928-A1 | Cyclopentanone derivative | PTGIS, CYP51A1, TRPA1 | RAB9A 4009/4885KDM4E 2486/4885L3MBTL1 4713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.